Adaptive Biotechnologies Corporation Stock 12‑Month Price Target Raised to $28.94, Implies 9% Upside
Adaptive Biotechnologies' average stock price target increased from $28.31 to $28.94 by 8 analysts, with a range of $21 to $35. This suggests a 9% upside from the Oct. 9 closing price. The consensus rating remains 'Buy' with 8 Buys, 1 Hold, and 0 Sells.
How this was made
The 30-second read
Why it matters
A higher consensus price target can modestly improve sentiment, but it is not a substitute for new company-specific disclosures like trial results, FDA actions, or guidance.
Market read
Traders may monitor whether additional analysts follow with similar rationale, but the article itself does not introduce new operational or regulatory information.
What to watch
The article does not specify the rationale behind the target increase, nor whether any analyst changed their underlying assumptions, so traders should treat it as sentiment data rather than fundamental re-rating.
Background
The piece summarizes FactSet-derived analyst estimates: average PT, range, and consensus rating.
Ticker impact
Adaptive Biotechnologies price target was raised from $28.31 to $28.94, with consensus still “Buy” across 9 analysts.
Mild upward bias as traders price in improved analyst expectations, with limited follow-through risk if no new catalysts emerge.
The only disclosed change is an average price-target increase and reiterated “Buy” consensus; there is no mention of new clinical, regulatory, or financial data.
Market effects
Limited read-through for biotech broadly, since this is a single-name analyst target update without new trial or regulatory milestones.
None indicated.
None indicated.
Counterpoint
Price-target revisions can lag or reflect sentiment rather than new information; without fresh trial/regulatory catalysts, the stock may not sustain the implied upside.
Key entities
- companyAdaptive Biotechnologies Corporation
US-listed biotech subject of the analyst price-target update described in the article.